B-cell prolymphocytic leukemia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Carlos Lopez (talk | contribs) No edit summary |
Carlos Lopez (talk | contribs) |
||
Line 2: | Line 2: | ||
{{B-cell prolymphocytic leukemia}} | {{B-cell prolymphocytic leukemia}} | ||
==Epidemiology and demographics== | ==Epidemiology and demographics== | ||
* | |||
* | ===Age=== | ||
* | * B-cell prolymphocytic leukemia is around 65-69 years median age<ref name=B-PLL>{{cite web | title = National cancer institute| url = http://seer.cancer.gov/seertools/hemelymph/51f6cf58e3e27c3994bd53f9/ }}</ref> | ||
* | |||
===Incidence=== | |||
* B-cell prolymphocytic leukemia incidence is ~1% of lymphocytic leukemias | |||
===Gender=== | |||
* There is no male or female predominance in B-cell prolymphocytic leukemia | |||
===Survival=== | |||
* There is 30-50 months median survival for this disease. | |||
==References== | ==References== |
Revision as of 14:19, 6 October 2015
B-cell prolymphocytic leukemia |
Differentiating B-cell prolymphocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
B-cell prolymphocytic leukemia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of B-cell prolymphocytic leukemia epidemiology and demographics |
FDA on B-cell prolymphocytic leukemia epidemiology and demographics |
CDC on B-cell prolymphocytic leukemia epidemiology and demographics |
B-cell prolymphocytic leukemia epidemiology and demographics in the news |
Blogs on B-cell prolymphocytic leukemia epidemiology and demographics |
Directions to Hospitals Treating B-cell prolymphocytic leukemia |
Risk calculators and risk factors for B-cell prolymphocytic leukemia epidemiology and demographics |
Epidemiology and demographics
Age
- B-cell prolymphocytic leukemia is around 65-69 years median age[1]
Incidence
- B-cell prolymphocytic leukemia incidence is ~1% of lymphocytic leukemias
Gender
- There is no male or female predominance in B-cell prolymphocytic leukemia
Survival
- There is 30-50 months median survival for this disease.